Dec. 17, 2020: HIV-related mortality in the U.S.; trends in extensive multidrug resistance; 96-week fostemsavir data; statins for microbial cancer prevention.
Most people living with HIV will never need fostemsavir. But for those who do, the drug can be a life-saver—and that is pretty epic.
Nov. 5, 2020: Success of direct referrals at re-linking people to HIV care; stable housing = viral suppression; modern-day rates of virologic failure; how pharmacy type affects HIV treatment outcomes.
Oct. 29, 2020: Diabetes incidence on INSTIs vs. NNRTIs vs. protease inhibitors; can NRTIs fight diabetes?; from TDF to TAF in HIV/HBV-coinfected people; assessing neurocognitive impacts of older two-drug regimens.
Oct. 22, 2020: Impact of COVID-19 shutdowns on HIV viral suppression; unsuppressed HIV viral load despite no treatment failure; point-of-care rapid testing vs. lab testing; it's not about "what," it's about "when."
Richard Jefferys of Treatment Action Group discusses the pipeline for new modalities being explored for treatment, PrEP, vaccine, and cure.
April 23, 2020: The corps of front-line care providers with HIV-specific experience is aging and retiring, leaving behind a growing need for quality care. We examine recent research and analysis that both describes that need and offers interventions to meet it.
Jan. 30, 2020: Polypharmacy vs. drug interaction risk among people living with HIV as they age; cost-effectiveness of ibalizumab; PrEP persistence on Medicaid vs. private health coverage.
Dec. 5, 2019: The value of pre-treatment drug resistance testing; resistance rates among viremic Americans; persistent pneumonia incidence among people with HIV; mixed HIV prevention results for the U.S. National HIV Strategy.
June 27, 2019: Long-term viability of NRTI-free salvage therapy; factors associated with HIV treatment interruption; evolution of frailty risk among older people; skin and soft tissue infections among people with HIV.